Management of a hypertensive ulcer with an epidermal growth factor-based formulation.
This rare ulcer was treated with a human recombinant epidermal growth factor-based formulation and antihypertensive drugs. Full granulation was achieved in 49 days and complete wound closure in 79 days. No adverse events were reported.